Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med.2000;124:672-681.
Kurman RJ, Henson DE, Herbst AL.
et al. Interim guidelines for management of abnormal cervical cytology. JAMA.1994;271:1866-1869.
Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? Obstet Gynecol.1998;91:973-976.
Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with
low-grade cytologic abnormalities. Obstet Gynecol.1995;85:202-210.
Ferris DG, Wright Jr TC, Litaker MS.
et al. Triage of women with ASCUS and LSIL on Pap smear reports. J Fam Pract.1998;46:125-134.
Manos MM, Kinney WK, Hurley LB.
et al. Identifying women with cervical neoplasia. JAMA.1999;281:1605-1610.
Wright Jr TC, Lorincz A, Ferris DG.
et al. Reflex HPV DNA testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol.1998;178:962-966.
Solomon D, Schiffman M, Tarrone R. Comparison of three management strategies for patients with atypical
squamous cells of undetermined significance. J Natl Cancer Inst.2001;93:293-299.
Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for
cervical cancer in HIV-infected women. Ann Intern Med.1999;130:97-107.
Goldie SJ, Freedberg KA, Weinstein MC.
et al. Cost effectiveness of human papillomavirus testing to augment cervical
cancer screening in women infected with the human immunodeficiency virus. Am J Med.2001;111:140-149.
Goldie SJ, Kuhn L, Denny L.
et al. Policy analysis of cervical cancer screening strategies in low-resource
Wright TC, Ferenczy AF, Kurman RJ. Precancerous lesions of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the
Female Genital Tract. 4th ed. New York, NY: Springer-Verlag; 1994:229-278.
Surveillance, Epidemiology, End Results (SEER) Cancer Statistics
Review, 1973-1994. Bethesda, Md: National Cancer Institute; 1997. Available at: http://www-seer.ims.nci.nih.gov. Accessed August 1, 2001.
Schiffman M. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst.1995;87:1345-1347.
Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes K, Mardh P, Sparling P, et al, eds. Sexually Transmitted Disease. 3rd ed. New York, NY: McGraw-Hill; 1999:347-360.
Schlecht NF, Kulaga S, Robitaille J.
et al. Persistant human papillomavirus infection as a predictor of cervical
intraepithelial neoplasia. JAMA.2001;286:3106-3114.
Solomon D, Davey DD, Moriarty A.
et al. Terminology for Reporting the Results of Cervical
Cytology. Bethesda, Md: National Cancer Institute; 2001.
Available at: http://bethesda2001.cancer.gov/terminology.html. Accessed February 1, 2002.
Sherman ME, Tabbara SO, Scott DR.
et al. ‘ASCUS, rule out HSIL.'. Mod Pathol.1999;12:335-342.
Malik SN, Wilkinson EJ, Drew PA.
et al. Do qualifiers of ASCUS distinguish between low- and high-risk patients? Acta Cytol.1999;43:376-380.
Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
Hildesheim A, Schiffman MH, Gravitt PE.
et al. Persistence of type-specific human papillomavirus infection among cytologically
normal women. J Infect Dis.1994;169:235-240.
Ho GYF, Bierman R, Beardsley L.
et al. Natural history of cervicovaginal papillomavirus infection in young
women. N Engl J Med.1998;338:423-428.
Liu T, Seng-jaw S, Alvarez R, Butterworth Jr C. A longitudinal analysis of human papillomavirus 16 infection, nutritional
status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev.1995;4:373-380.
Cuzick J. Human papillomavirus testing for cerical screening. Health Technol Assess.1999;3:14.
Lawson HW, Lee NC, Thames SF.
et al. Cervical cancer screening among low-income women. Obstet Gynecol.1998;92:745-752.
Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright Jr TC. Human papillomavirus infection in women infected with the human immunodeficiency
virus. N Engl J Med.1997;337:1343-1349.
McCrory D, Mather D, Bastain L.
et al. Evaluation of Cervical Cytology: Evidence Report/Technology
Assessment No.5. Rockville, Md: Agency for Health Care Policy and Research; 1999.
AHCPR publication 99-E010.
Myers E, McCrory D, Nanda K, Matchar D. Mathematical model for the natural history of human papillomavirus
infection and cervical carcinogenesis. Am J Epidemiol.2000;151:1158-1171.
Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development
of high-grade lesions in women with minor cervical abnormalities. Int J Cancer.1996;69:364-368.
Syrjanen K, Kataja V, Yliskoski M.
et al. Natural history of cervical human papillomavirus lesions does not substantiate
the biologic relevance of the Bethesda System. Obstet Gynecol.1992;79:675-682.
Ho GY, Burk RD, Klein S.
et al. Persistent genital human papillomavirus infection as a risk factor
for persistent cervical dysplasia. J Natl Cancer Inst.1995;87:1365-1371.
Ostor AG. Natural history of cervical intraepithelial neoplasia. Int J Gynecol Pathol.1993;12:186-192.
Melnikow J, Nuovo J, Willan AR.
et al. Natural history of cervical squamous intraepithelial lesions. Obstet Gynecol.1998;92(4 pt 2):727-735.
Ho GY, Kadish AS, Burk RD.
et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical
intra-epithelial neoplasia. Int J Cancer.1998;78:281-285.
Hopman EH, Rozendaal L, Voorhorst FJ.
et al. High risk human papillomavirus in women with normal cervical cytology
prior to the development of abnormal cytology and colposcopy. BJOG.2000;107:600-604.
Rozendaal L, Walboomers JM, van der Linden JC.
et al. PCR-based high-risk HPV test in cervical cancer screening gives objective
risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer.1996;68:766-769.
Ellerbrock TV, Chiasson MA, Bush TJ.
et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected
Koutsky LA, Holmes KK, Critchlow CW.
et al. A cohort study of the risk of cervical intraepithelial neoplasia grade
2 or 3 in relation to papillomavirus infection. N Engl J Med.1992;327:1272-1278.
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ.
et al. Relation of human papillomavirus status to cervical lesions and consequences
for cervical-cancer screening: a prospective study. Lancet.1999;354:20-25.
Remmink AJ, Walboomers JM, Helmerhorst TJ.
et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical
lesions is associated with progressive disease. Int J Cancer.1995;61:306-311.
Lonky NM, Sadeghi M, Tsadik GW, Petitti D. The clinical significance of the poor correlation of cervical dysplasia
and cervical malignancy with referral cytologic results. Am J Obstet Gynecol.1999;181:560-566.
Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology. Arch Pathol Lab Med.2000;124:665-671.
Statistical Abstract of the United States: Consumer Price Index:
All Urban Consumers. Washington, DC: National Center for Health Statistics; 2001. Available at:
http://www.cdc.gov/nchswww/data/gm291_1.pdf. Accessed September 1, 2001.
Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol.1995;141:680-689.
Nanda K, McCrory DC, Myers ER.
et al. Accuracy of the Papanicolaou test in screening for and follow-up of
cervical cytologic abnormalities: a systematic review. Ann Intern Med.2000;132:810-819.
Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol.2000;95:821-827.
Ferris DG, Wright Jr TC, Litaker MS.
et al. Comparison of two tests for detecting carcinogenic HPV in women with
Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract.1998;46:136-141.
Lin CT, Tseng CJ, Lai CH.
et al. High-risk HPV DNA detection by Hybrid Capture II. J Reprod Med.2000;45:345-350.
Shlay JC, Dunn T, Byers T, Baron AE, Douglas Jr JM. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk
assessment and human papillomavirus testing in women with atypia on Papanicolaou
smears. Obstet Gynecol.2000;96:410-416.
Hutchinson ML, Zahniser DJ, Sherman ME.
et al. Utility of liquid-based cytology for cervical carcinoma screening. Cancer.1999;87:48-55.
Diaz-Rosario LA, Kabawat SE. Performance of a fluid-based, thin-layer Papanicolaou smear method
in the clinical setting of an independent laboratory and an outpatient screening
population in New England. Arch Pathol Lab Med.1999;123:817-821.
Ashfaq R, Gibbons D, Vela C.
et al. ThinPrep Pap test. Acta Cytol.1999;43:81-85.
Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol.2000;23:19-22.
Quddus MR, Sung CJ, Steinhoff MM.
et al. Atypical squamous metaplastic cells. Cancer.2001;93:16-22.
Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing
is used as an adjunct to Papanicolaou smear in the triage of women with cervical
cytologic abnormalities. Am J Obstet Gynecol.1999;181:382-386.
Helms LJ, Melnikow J. Determining costs of health care services for cost-effectiveness analyses. Med Care.1999;37:652-661.
Muller C, Mandelblatt J, Schechter C. The Costs and Effectiveness of Screening for Cervical
Cancer in Elderly Women. Washington, DC: Office of Technology Assessment; 1990.
Shireman TI, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Int J Technol Assess Health Care.2001;17:146-152.
US Bureau of Labor Statistics. Statistical Abstract of the United States. Washington, DC: US Government Printing Office; 2001. Publication
Moscicki AB. Human papillomavirus infection in adolescents. Pediatr Clin North Am.1999;46:783-807.
Burk RD, Kelly P, Feldman J.
et al. Declining prevalence of cervicovaginal human papillomavirus infection
with age is independent of other risk factors. Sex Transm Dis.1996;23:333-341.
Bauer HM, Hildesheim A, Schiffman MH.
et al. Determinants of genital human papillomavirus infection in low-risk
women in Portland, Oregon. Sex Transm Dis.1993;20:274-278.
Melkert PJ, Hopman E, van den Brule J.
et al. Prevalence of HPV in cytomorphlogically normal cervical smears, as
determined by the polymerase chain reaction, is age-dependent. Int J Cancer.1993;53:919-923.
Burk RD, Ho GYF, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk
factors for genital human papillomavirus infection in young women. J Infect Dis.1996;174:679-689.
Kotloff KL, Wasserman SS, Russ K.
et al. Detection of genital human papillomavirus and associated cytological
abnormalities among college women. Sex Transm Dis.1998;25:243-250.
Sellors JW. Cervical cancer prevention for all Canadians. Can Fam Physician.1999;45:245-247, 252-254.
Moscicki AB, Shiboski S, Broering J.
et al. The natural history of human papillomavirus infection as measured by
repeated DNA testing in adolescent and young women. J Pediatr.1998;132:277-284.
Franco E, Villa L, Sobrinho J.
et al. Epidemiology of acquisition and clearance of cervical human papillomavirus
infection in women from a high-risk area for cervical cancer. J Infect Dis.1999;180:1415-1423.
Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control.1992;3:125-136.
Ponten J, Adami HO, Bergstrom R.
et al. Strategies for global control of cervical cancer. Int J Cancer.1995;60:1-26.
Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer.1997;72:210-216.
Wright Jr TC, Cox JT, Massad LS.
et al. 2001 consensus guidelines for the management of women with cervical
cytological abnormalities. JAMA.2002;287:2120-2129.
Gold M, Franks P, McCoy K, Fryback DG. Toward consistency in cost-utility analyses. Med Care.1998;36:778-792.
Fryback D, Dasbach E, Klein R.
et al. Initial catalog of health-state quality factors. Med Decis Making.1993;13:89-102.
Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal
cytology. Obstet Gynecol.2000;96:219-223.
Results from the National Breast and Cervical Cancer Early Detection
Program, October 31, 1991-September 30, 1993. MMWR Morb Mortal Wkly Rep.1994;43:530-534.
Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses
in northern New England. Pediatrics.1999;103:539-545.
Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological
screening. Int J Cancer.1997;71:159-165.
Pettersson F, Bjorkholm E, Naslund I. Evaluation of screening for cervical cancer in Sweden. Int J Epidemiol.1985;14:521-527.
Cox JT, Wilkinson EJ, Lonky N.
et al. Management guidelines for the follow-up of atypical squamous cells
of undetermined significance (ASCUS). J Lower Genital Tract.2000;4:99-105.
Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou
Eddy DM. Screening for cervical cancer. Ann Intern Med.1990;113:214-226.
Fahs MC, Plichta SB, Mandelblatt JS. Cost-effective policies for cervical cancer screening. Pharmacoeconomics.1996;9:211-230.
Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost-effectiveness of cervical cancer screening for the elderly. Ann Intern Med.1992;117:520-527.
Graham JD, Corso PS, Morris JM.
et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health.1998;19:125-152.
Weinstein MC. High-priced technology can be good value for money. Ann Intern Med.1999;130:857-858.
Kuntz KM, Goldie SJ. Defining the effects of population heterogeneity in Markov models. Med Decis Making.2000;20:484.
Goldie SJ, Kuntz KM. Modeling compliance in cost-effectiveness analyses of screening programs. Med Decis Making.2001;20:529.
Barry M. Health decision aids to facilitate shared decision making in office
practice. Ann Intern Med.2002;136:127-135.